Evidence map›Paper›PMID 35437727›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

Systems Biology to Address Unmet Medical Needs in Neurological Disorders.

Masha G Savelieff, Mohamed H Noureldein, Eva L Feldman

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Painful Diabetic Neuropathy: The Need for New Approaches.Journal of diabetes science and technology · 2024
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Masha G SavelieffNeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, MI, USA.
Mohamed H NoureldeinNeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, MI, USA.
Eva L FeldmanNeuroNetwork for Emerging Therapies, University of Michigan, Ann Arbor, MI, USA. efeldman@umich.edu.
University of Michigan–Ann Arbor · US

Funding

Integrated Systems Biology Approach to Diabetic Microvascular ComplicationsR24DK082841 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ABCOUWER, STEVEN F, BROSIUS, FRANK C · 2008 to 2020
$13.1M
Mapping the ALS Exposome to Gain New Insights into Disease Risk and PathogenesisR01ES030049 · NIEHS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BATTERMAN, STUART A, FELDMAN, EVA LUCILLE · 2020 to 2024
$3.5M
Metabolomic Signatures Linking ALS to Persistent Organic Pollutant ExposuresR01TS000289 · TS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FELDMAN, EVA LUCILLE · 2018 to 2020
$1.5M
ATSDR CDC HHS R01 TS000289NIDDK NIH HHS R24 DK082841NIEHS NIH HHS R01 ES030049
6 · The paper itself

Abstract

Neurological diseases are highly prevalent and constitute a significant cause of mortality and disability. Neurological disorders encompass a heterogeneous group of neurodegenerative conditions, broadly characterized by injury to the peripheral and/or central nervous system. Although the etiology of neurological diseases varies greatly, they share several characteristics, such as heterogeneity of clinical presentation, non-cell autonomous nature, and diversity of cellular, subcellular, and molecular pathways. Systems biology has emerged as a valuable platform for addressing the challenges of studying heterogeneous neurological diseases. Systems biology has manifold applications to address unmet medical needs for neurological illness, including integrating and correlating different large datasets covering the transcriptome, epigenome, proteome, and metabolome associated with a specific condition. This is particularly useful for disentangling the heterogeneity and complexity of neurological conditions. Hence, systems biology can help in uncovering pathophysiology to develop novel therapeutic targets and assessing the impact of known treatments on disease progression. Additionally, systems biology can identify early diagnostic biomarkers, to help diagnose neurological disease preceded by a long subclinical phase, as well as define the exposome, the collection of environmental toxicants that increase risk of certain neurological diseases. In addition to these current applications, there are numerous potential emergent uses, such as precision medicine.

Indexed as

Neurodegenerative DiseasesSystems BiologyDisease ProgressionHumansProteomeTranscriptomeProteomeAlzheimer’s diseaseAmyotrophic lateral sclerosisDiabetesInclusion body myositisMotor neuron diseaseNeurodegenerative diseaseObesityParkinson’s diseasePeripheral neuropathy

Identifiers

PMID35437727
PMCPMC9446424
OpenAlexW4225871151

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.